Drug intelligence / Profile preview

anti-EpCAM-UPGs-MX

Development stage
Preclinical
Lead developer
Southeast University
Modality
Small Molecules, Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

**anti-EpCAM-UPGs-MX** is an experimental EpCAM-targeted theranostic nanomedicine developed for **hepatocellular carcinoma**. It consists of PEGylated upconversion nanoparticle-based micelles carrying the antineoplastic and photosensitizing agent **mitoxantrone**, with an anti-EpCAM antibody grafted to the micelle surface to promote delivery to EpCAM-positive hepatocellular carcinoma cells. Following intravenous administration in preclinical models, the formulation supported magnetic resonance and upconversion-luminescence imaging while producing combined mitoxantrone-mediated chemotherapy and photodynamic therapy after optical activation. The published work reported improved tumor-targeted imaging and antitumor activity relative to non-targeted comparator micelles.

Other names
anti-EpCAM-UPGs-MX
02

Targets

DNATOP2A (DNA topoisomerase II)EPCAM (Epithelial cell adhesion molecule)

Beyond the preview

Go deeper on anti-EpCAM-UPGs-MX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-EpCAM-UPGs-MX.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call